

# Acquired/intratumoral mutation of *KRAS* during metastatic progression of colorectal carcinogenesis

KAZUNORI OTSUKA<sup>1\*</sup>, RIKA SATOYOSHI<sup>2\*</sup>, HIROSHI NANJO<sup>3</sup>, HIDEAKI MIYAZAWA<sup>4</sup>, YUKI ABE<sup>4</sup>, MASAMITSU TANAKA<sup>2</sup>, YUZO YAMAMOTO<sup>4</sup> and HIROYUKI SHIBATA<sup>1</sup>

Departments of <sup>1</sup>Clinical Oncology, <sup>2</sup>Molecular Medicine and Biochemistry, <sup>3</sup>Pathology, and <sup>4</sup>Gastroenterological Surgery, Graduate School of Medicine, Akita University, Akita 010-8543, Japan

Received August 30, 2011; Accepted November 22, 2011

DOI: 10.3892/ol.2011.543

**Abstract.** Mutations at codons 12 and 13 of the *KRAS* gene have been identified as level I predictive biomarkers against the treatment of advanced colorectal cancer with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies. It is thought that the genetic analysis of *KRAS* mutations associated with metastatic colorectal cancer can be routinely conducted using DNA obtained on one occasion from one organ, from the primary or a metastatic site, whichever is preferentially available. However, the issue of tumor heterogeneity resulting from acquired/intratumoral mutations remains. Recently, the possibility of acquired/intratumoral mutations in the *KRAS* gene has been reported by two research groups and has ranged from 7.4 to 15.4%. Specimens were collected from advanced colorectal cancer patients with resected primary, and at least one metastatic, site. Direct sequence analysis was performed for *KRAS*, *BRAF* and *PIK3CA*, and immunohistochemistry for glutathione S-transferase II (GSTP) and EGFR. In the current study, we identified an acquired mutation rate of approximately 11.1% in the *KRAS* gene (1/9). This figure is not negligible. Our observation indicates, particularly in the case of metastatic recurrence after a long interval, that there may be considerable tumor heterogeneity resulting from acquired or intratumoral mutations of the *KRAS* gene.

## Introduction

In the last decade, two anti-epidermal growth factor receptor monoclonal antibodies (EGFR mAbs), cetuximab and panitumumab, were approved for the treatment of EGFR-positive colorectal cancer (CRC) (1,2). EGFR signals are trans-

duced by *KRAS* and follow two signaling pathways, the RAS-RAF-MEK-ERK and RAS-PI3 kinase-AKT/PKB pathways. Mutations at codons 12 and 13 of the *KRAS* gene have been identified as a level I predictive biomarker against the treatment of advanced CRC with anti-EGFR mAbs according to the College of American Pathologists (CAP) level of evidence classification; that is, these mutations have been definitively proven as biomarkers based on evidence from multiple, statistically robust, published trials, and they are generally used in patient management (3). *BRAF* is a serine-threonine kinase located downstream of *KRAS*, which is a component of the RAS-RAF-MEK-ERK signaling pathway (4). A valine to glutamate substitution mutation at codon 600 (V600E) of the *BRAF* gene is a hot spot and is observed in 5-22% of CRCs (4). *BRAF* has a level IIA CAP predictive value, which means that extensive biological and clinical studies have repeatedly shown it to have predictive value for therapy; however, this remains to be validated in statistically robust studies (3). Phosphatidylinositol 3 kinase (PI3K) is composed of a regulatory and a catalytic subunit (5). The latter is encoded by the *PIK3CA* gene. Mutations in *PIK3CA* are observed in 15% of CRCs (6); approximately 70% of *PIK3CA* mutations are located at exon 9 [a glutamic acid to lysine substitution at codons 542 (E542K) and 545 (E545K)] and 20% at exon 20 [a histidine to arginine substitution at codon 1047 (H1047R)] (7). *PIK3CA* has a level IIB CAP predictive value, indicating that it has shown promise in multiple studies; however, sufficient data for its inclusion in categories I or IIA are lacking (3). Although EGFR is a direct target of EGFR mAbs, the EGFR expression level does not have any predictive value in a clinical setting (3). Glutathione S-transferase II (GSTP) is involved in detoxification and may be used as a cancer marker (8). Overexpression of GSTP has been reported to be closely correlated with *KRAS* mutations; the GSTP expression level is higher in CRCs with *KRAS* mutations compared to wild-type *KRAS* (9). Expression of mutant *KRAS* activates GSTP at a transcriptional level. If this observation is reproducible in a clinical setting, the presence of a *KRAS* mutation may be distinguishable by GSTP immunohistochemistry (IHC).

One report, analyzing 233 genes, indicated that there may be differences in as few as 3% of genes between primary and metastatic sites (10). Moreover, mutations in the *KRAS*, *BRAF* and *PIK3CA* genes occur around the adenoma stage (10). In

---

*Correspondence to:* Dr Hiroyuki Shibata, Department of Clinical Oncology, Graduate School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan  
E-mail: hiroyuki@med.akita-u.ac.jp

\*Contributed equally

**Key words:** *KRAS*, *BRAF*, *PIK3CA*, colorectal cancer, acquired/intratumor mutation

these situations, it is thought that the routine performance of one genetic test for *KRAS* mutations associated with metastatic CRC using DNA obtained from one organ, either from the primary or a metastatic site, whichever is preferentially available, is sufficient. However, the possibility of considerable tumor heterogeneity remains an issue. Recently, the possibility of acquired or intratumoral mutations of the *KRAS* gene was reported (11,12). Although the number of cases surveyed was small, the frequency of acquired mutations identified was not negligible. In our study, we identified 9 cases in which synchronous or metachronous metastasis was resectable, together with the primary CRC, and determined the status of target genes, including *KRAS*, *BRAF*, *PIK3CA*, *EGFR* and *GSTP* at each of these sites to determine the incidence of acquired mutations that may affect treatment with *EGFR* mAbs.

## Materials and methods

**Patient selection.** Samples were collected from the primary site, and from at least one site of distant synchronous or metachronous metastasis, from 9 patients with colorectal adenocarcinoma whose tumors were resected at Akita University Hospital (Japan). This study was approved by the institutional ethics committee for clinical studies at Akita University, Graduate School of Medicine, on July 20th, 2010, and each of the patients gave their informed consent to the procedure.

**Direct sequencing.** Direct sequencing of codons 12 and 13 of *KRAS*, codon 600 of *BRAF*, and exons 9 and 20 of *PIK3CA* was outsourced to SRL Inc. (Tokyo, Japan) or Falco Biosystems Ltd. (Kyoto, Japan). Briefly, the tumor cell-rich area of a hematoxylin and eosin-stained section was identified by microscopy. Tissue was then removed from the same area of a deparaffinized, unstained section. DNA from sections of that tissue sample was then isolated using the QIAamp FFPE Tissue kit (QIAGEN K.K.; Tokyo, Japan) and exon 1 of the *KRAS* gene, exon 15 of the *BRAF* gene, and exons 9 and 20 of the *PIK3CA* gene were amplified by polymerase chain reaction (PCR). The PCR products were visualized using agarose gel electrophoresis with ethidium bromide staining. PCR DNA fragments were directly sequenced using an ABI 3130 Genetic Analyzer (Applied Biosystems; Foster City, CA, USA) according to the manufacturer's instructions.

**Immunohistochemistry.** Almost all of the procedures were performed using a BenchMark XT IHC/ISH Staining Module (Roche Diagnostics K.K.; Tokyo, Japan). Deparaffinized 4- $\mu$ m specimens were used for IHC along with anti-human *EGFR* mouse monoclonal antibody (clone 2-18C9, Dako Japan; Tokyo, Japan), anti-human *KRAS* mouse monoclonal antibody (clone ab55391, Abcam Japan; Tokyo, Japan), and polyclonal rabbit anti-human *GSTP* (311-H, Medical and Biological Laboratories Co., Ltd.; Nagoya, Japan). Immunopositivity for *EGFR* was judged as positive if there were >0.1% positive cells. Immunoreactivities for *KRAS* and *GSTP* were graded as negative (0 to <10% positive cells), + ( $\geq$ 10 to <30% positive cells), ++ (>30 to <70% positive cells) and +++ (>70% positive cells). The percentage of immunopositive cells was calculated by counting at least 400 cancer cells in contiguous fields with the greatest immunopositivity.

## Results

**Patient characteristics.** A total of 9 patients (3 females and 6 males) were included in this observational study. The median age was 67 years (range, 56-75). The patients were diagnosed as having CRC adenocarcinomas (2 rectal and 7 colon cancers). Three synchronous and 5 metachronous liver metastases, 2 synchronous and 5 metachronous lung metastases, and 1 synchronous ovarian metastasis were included. Resection of the primary region and at least one metastasis site was conducted either simultaneously or independently (Table I).

**Sequence analyses of the *KRAS*, *BRAF* and *PIK3CA* genes.** Regarding *KRAS* mutations, a glycine to aspartic acid mutation at codon 12 (G12D) was observed in the primary region of case 5, and a glycine to aspartic acid mutation at codon 13 (G13D) was observed in the primary region of case 1. In the remaining cases, no mutations were observed in the primary regions (Table I, Fig. 1A). The *KRAS* mutation frequency in the primary region was thus estimated to be 22.2% (2/9). At the metastatic sites, a G12D mutation was observed in both the lung and liver metastatic sites of case 5, and a G13D mutation was observed in the liver metastatic site of case 1. In case 8, a *KRAS* mutation involving a glycine to valine substitution at codon 12 (G12V) was observed in the liver metastatic site (Fig. 1B). In the remaining cases, no mutations were observed in the metastatic regions. The mutation frequency of *KRAS* at each metastatic site was thus estimated to be 27.3% (3/11).

**No *BRAF* mutations were observed at exon 15 in the primary regions of all cases other than for case 7 (Fig. 1C).** In case 7, a leucine to arginine mutation was observed at codon 597 (L597R) (Fig. 1D). This L597R mutation was also observed at the site of lung metastasis in case 7. No other mutations were observed at any of the remaining metastatic sites. According to the genomic information found in the Catalogue of Somatic Mutations of Cancer (COSMIC), released by the Sanger Institute, L597R was confirmed as a somatic variant (<http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=sample&id=749760>).

**As for *PIK3CA*,** no mutations were observed at exons 9 and 20 in the primary region of all cases with the exception of case 4 (Fig. 1E). In case 4, a glutamine to glutamic acid mutation was observed at codon 546 (Q546E) at exon 9 (Fig. 1F). This Q546E mutation was also observed at the site of liver metastasis in case 4. No mutations were observed at the remaining metastatic sites. Q546E was confirmed as a somatic variant by COSMIC ([http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=mut\\_summary&id=6147](http://www.sanger.ac.uk/perl/genetics/CGP/cosmic?action=mut_summary&id=6147)).

**Immunohistochemical analyses of *EGFR*, *KRAS* and *GSTP*.** Immunopositivity for *EGFR* was observed at the primary site in 4 out of the 9 cases (cases 2, 3, 4 and 9) (Table I). A corresponding immunopositivity was observed at the metastatic sites in these 4 cases. However, a different immunopositivity was observed for cases 7 and 8, where the immunoreactivity for *EGFR* was negative at the primary site but positive at the metastatic site (Fig. 2A and B). No immunopositivity was observed at the primary or metastatic sites in the remaining cases.

Table I. Clinical profiling of 9 mCRC patients and their biomarker status.

Characteristic	Case 1	Case 2	Case 3	Case 4	Case 5	Case 6	Case 7	Case 8	Case 9
Age	72	66	65	56	67	75	71	72	57
Gender	M	M	M	F	M	F	M	M	F
Primary	R	A	R	A	A	A	A	T	S
Hist	Wel-mod	Mod	Mod>wel	Mod	Mod	Wel	Mod	Wel	Wel>mod
Meta	Liver	Liver	Liver Lung	Liver	Liver Lung	Liver	Lung	Liver LN	Ovary
Occurence	S	S	M M	S	S S	M	M	M M	S
Interval (D)	-	-	483 1435	-	- -	382	1652	2321 2321	-
KRAS	G13D G13D	Wild Wild	Wild Wild Wild	Wild Wild	G12D G12D G12D	Wild Wild	Wild Wild	Wild G12V G12V	Wild Wild
BRAF	Wild Wild	Wild Wild	Wild Wild Wild	Wild Wild	Wild Wild Wild	Wild Wild	L597R L597R	Wild Wild ND	Wild Wild
PIK3CA	Wild Wild	Wild Wild	Wild Wild Wild	Q546E Q546E	Wild Wild Wild	Wild Wild	Wild Wild	Wild Wild ND	Wild Wild
EGFR	(-) (-)	(+) (+)	(+) (+) (+)	(+) (+)	(-) (-) (-)	(-) (-)	(-) (+)	(-) (+) ND	(+) (+)
GSTP	(+++) (++)	(+++) (++)	(+++) (++) ND	(+++) (+++)	(++) (+++) ND	(-) (-)	(+) ND	(-) (-) ND	(-) (-)

S, synchronous metastasis; M, metachronous metastasis; Wel, well-differentiated; Mod, moderately differentiated; ND, non-defined. Interval indicates days between primary and metastatic lesion resection. CRC, colorectal cancer; LN, lymph node; GSTP, glutathione S-transferase II; EGFR, epidermal growth factor receptor; R, rectal; A, ascending; T, transverse; S, sigmoid.

*Immunoreactivity for KRAS is apparently not dependent on the mutational status of KRAS (Table I, Fig. 2C and D).* Moreover, a correlation between the immunoreactivities or mutational status was not observed between KRAS and GSTP in this study (Fig. 2E-G). Therefore, we were unable to diagnose the mutational status of KRAS by GSTP IHC in a clinical setting.

*Case presentation.* In this observational study, a difference in the KRAS gene status between the primary and metastatic sites was observed in 1 (case 8) out of 9 cases (11.1%). This was independently confirmed by a separate analysis. Furthermore, the same KRAS mutation was detected in the resected mediastinal lymph node in case 8. Differences in immunopositivity for EGFR were observed in 2 (cases 7 and 8) out of 9 cases (22.2%). Case 7 was a 71-year-old male with ascending colon cancer. Following the primary resection, a 5-fluorouracil (5-FU) regimen (RPMI regimen) was administered for 6 months as adjuvant chemotherapy but 1,652 days following resection of the primary site, metastasis was evident in one lung and the site was resected (13). Modified leucovorin, fluorouracil

and oxaliplatin (mFOLFOX6) was then administered as adjuvant chemotherapy for 180 days following resection until completion (April, 2011). Case 8 was a 72-year-old male with transverse colon cancer. Following primary resection, adjuvant chemotherapy was similarly administered for 6 months. However, 2,321 days after the primary resection, metastasis was detected at one site in the liver and in one mediastinal lymph node. The two sites were resected and mFOLFOX6 initiated as adjuvant chemotherapy (14). However, on day 159, mFOLFOX6 was terminated due to lung and abdominal lymph node metastases. A folinic acid-fluorouracil-irinotecan (FOLFIRI) regimen was then initiated and continued for 232 days up to the time of writing (15).

## Discussion

In this study, we identified a possibility that acquired or intratumoral mutations may occur in the EGFR signaling pathway during CRC progression. Regarding KRAS, mutations in codons 12 and 13 were observed in 2 out of 9 cases at the primary site, and an acquired mutation was found in 1 case at a distal




Figure 1. Sequence analyses of *KRAS*, *BRAF* and *PIK3CA*. The representative sequence analysis is shown for each case. Heterozygous mutations are shown by perpendicular lines.




Figure 2. Immunohistochemical analyses of EGFR, KRAS and GSTP. (A) Negative immunoreactivity for EGFR at the primary lesion and (B) positive immunoreactivity at the site of lung metastasis in case 7, (C) negative immunoreactivity for KRAS (G12D) at the primary lesion and (D) positive immunoreactivity for KRAS (G12D) at the site of lung metastasis in case 5, (E) immunoreactivity for GSTP is denoted by (++) at the primary lesion, (F) (+++) at the site of liver metastasis, and (G) (-) at the site of lung metastasis in case 5; all sites had the same KRAS G12D mutation. EGFR, epidermal growth factor receptor; GSTP, glutathione S-transferase II; G12D, glycine to aspartic acid mutation at codon 12.

metastatic site. In previous reports, the mutation frequency of *KRAS* at codons 12 and 13 has ranged from 27 to 53% in CRC, which is similar to our finding (30%). The mutation frequencies of *BRAF* (V600E) and *PIK3CA* (exons 9 and 12) have been reported as 5-22% and 15%, respectively, in CRC. In our study, no oncogenic mutations of *BRAF* or *PIK3CA* were observed at either the primary or the metastatic sites. Differences in EGFR immunoreactivity were observed between the primary and metastatic sites in two instances, cases 7 and 8. In these two cases, the duration between the date of resection of the primary

site and the date of metastatic recurrence was much longer (1,652 and 2,321 days, respectively) than that for the other cases (7 synchronous and 7 metachronous metastatic sites). In the remaining cases, the duration between the date of resection of the primary site and the date of onset of metastatic recurrence ranged from 217 to 952 days (median, 395). Since protein is easily degraded, the IHC analysis of EGFR may be affected by long-term storage. Therefore, the failure to detect immunoreactivity at the primary sites in cases 7 and 8 may be due to protein degradation during long-term storage. However, the direct



sequencing of *KRAS* was successfully performed using DNA obtained from the archived specimens of the primary sites for these cases (Fig. 1). DNA is more stable than protein over longer periods; therefore, the quality of DNA in this study was sufficient for direct sequencing. In case 8, the possibility of an acquired or intratumoral mutation was suspected. The overall incidence of acquired or intratumoral mutations of *KRAS* was approximately 10% in this study, which is nearly identical to that of previous reports. Bouchahda *et al* reported acquired *KRAS* mutations (G12D and G13D) in 2 out of 13 cases (15.4%) (11). Richman *et al* reported intratumoral *KRAS* mutations at codons 12 and 13 in 5 out of 68 cases (7.4%) and an intratumoral *BRAF* mutation (V600E) in 2 cases (2.9%). Thus, in total, mutations in the EGFR pathway were identified in 7 out of 68 cases (10.3%) in their study (12). Although only 9 cases were analyzed in our study, each case had at least one resectable metastatic site and the total number of sites (combining primary and metastatic sites) was 18. Thus, it may be better to report an acquired mutation rate of approximately 11.1% (2/18). In conclusion, when metastatic recurrence occurs after a long interval, it is likely that acquired *KRAS* mutations may be identified.

### Acknowledgements

This study was supported by the Ministry of Health, Labour, and Welfare.

### References

- Vincenzi B, Zoccoli A, Pantano F, Venditti O and Galluzzo S: Cetuximab: from bench to bedside. *Curr Cancer Drug Targets* 10: 80-95, 2010.
- Giusti RM, Cohen MH, Keegan P and Pazdur R: FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer. *Oncologist* 14: 284-290, 2009.
- Ross JS, Torres-Mora J, Wagle N, Jennings TA and Jones DM: Biomarker-based prediction of response to therapy for colorectal cancer. *Am J Clin Pathol* 134: 478-490, 2010.
- Garnett MJ and Marais R: Guilty as charged: B-RAF is a human oncogene. *Cancer Cell* 6: 313-319, 2004.
- Garcia Z, Kumar A, Marques M, Cortes I and Carrera AC: Phosphoinositide 3-kinase controls early and late events in mammalian cell division. *EMBO J* 25: 655-661, 2006.
- De Roock W, Claes B, Bernasconi D, *et al*: Effects of *KRAS*, *BRAF*, *NRAS*, and *PIK3CA* mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. *Lancet Oncol* 11: 753-762, 2010.
- Samuels Y, Diaz LA Jr, Schmidt-Kittler O, *et al*: Mutant *PIK3CA* promotes cell growth and invasion of human cancer cells. *Cancer Cell* 7: 561-573, 2005.
- Aliya S, Reddanna P and Thyagaraju K: Does glutathione S-transferase Pi (GST-Pi) a marker protein for cancer? *Mol Cell Biochem* 253: 319-327, 2003.
- Miyaniishi K, Takayama T, Ohi M, *et al*: Glutathione S-transferase-pi overexpression is closely associated with K-ras mutation during human colon carcinogenesis. *Gastroenterology* 121: 865-874, 2001.
- Jones S, Chen WD, Parmigiani G, *et al*: Comparative lesion sequencing provides insights into tumor evolution. *Proc Natl Acad Sci USA* 105: 4283-4288, 2008.
- Bouchahda M, Karaboué A, Saffroy R, *et al*: Acquired *KRAS* mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. *Cancer Chemother Pharmacol* 66: 605-609, 2010.
- Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G and Quirke P: Intra-tumoral heterogeneity of *KRAS* and *BRAF* mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. *Anal Cell Pathol* 34: 61-66, 2011.
- Haller DG, Catalano PJ, Macdonald JS, O'Rourke MA, Frontiera MS, Jackson DV and Mayer RJ: Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. *J Clin Oncol* 23: 8671-8678, 2005.
- André T, Boni C, Navarro M, *et al*: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *J Clin Oncol* 27: 3109-3116, 2009.
- Tournigand C, André T, Achille E, *et al*: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. *J Clin Oncol* 22: 229-237, 2004.